BR112013009670A2 - compostos inibidores de catepsina s - Google Patents

compostos inibidores de catepsina s

Info

Publication number
BR112013009670A2
BR112013009670A2 BR112013009670A BR112013009670A BR112013009670A2 BR 112013009670 A2 BR112013009670 A2 BR 112013009670A2 BR 112013009670 A BR112013009670 A BR 112013009670A BR 112013009670 A BR112013009670 A BR 112013009670A BR 112013009670 A2 BR112013009670 A2 BR 112013009670A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
present
Prior art date
Application number
BR112013009670A
Other languages
English (en)
Inventor
Euibong Jemes Kim
Gary Gang Deng
Konstantinos Gavardinas
Matthew Allen Schiffler
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112013009670A2 publication Critical patent/BR112013009670A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos inibidores de catepsina s. a presente invenção refere-se a um composto de fórmula (i): ou um sal farmaceuticamente aceitável do mesmo. além disso, a presente invenção fornece uma composição farmacêutica compreendendo um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, com um diluente ou veículo farmaceuticamente aceitável. a presente invenção ainda fornece métodos para o tratamento de aneurisma da aorta abdominal, instabilidade de placa, asterosclerose, ou desordens autoimunes, tais como, artrite reumatóide, psoriase e lúpus, compreendendo a administração de uma quantidade terapeuticamente eficaz de um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo ou uma composição farmacêutica compreendendo um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo e um diluente ou veículo farmaceuticamente aceitável.
BR112013009670A 2010-10-19 2011-10-14 compostos inibidores de catepsina s BR112013009670A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39442410P 2010-10-19 2010-10-19
PCT/US2011/056244 WO2012054315A1 (en) 2010-10-19 2011-10-14 Cathepsin s inhibitor compounds

Publications (1)

Publication Number Publication Date
BR112013009670A2 true BR112013009670A2 (pt) 2016-07-12

Family

ID=44898195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009670A BR112013009670A2 (pt) 2010-10-19 2011-10-14 compostos inibidores de catepsina s

Country Status (13)

Country Link
US (1) US8227468B2 (pt)
EP (1) EP2630141A1 (pt)
JP (1) JP2013540154A (pt)
KR (1) KR20130093120A (pt)
CN (1) CN103153989A (pt)
AR (1) AR083364A1 (pt)
AU (1) AU2011318316A1 (pt)
BR (1) BR112013009670A2 (pt)
CA (1) CA2816033C (pt)
EA (1) EA201370052A1 (pt)
MX (1) MX2013004421A (pt)
TW (1) TWI402072B (pt)
WO (1) WO2012054315A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3061302A1 (en) * 2017-04-27 2019-10-23 Mochida Pharmaceutical Co., Ltd. Novel tetrahydronaphthyl urea derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703377D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
CA2428863A1 (en) * 2000-11-17 2002-05-23 Medivir Uk Limited Cysteine protease inhibitors
WO2002042278A2 (en) 2000-11-21 2002-05-30 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
PL205708B1 (pl) 2001-09-21 2010-05-31 Lilly Co Eli Związki agonistyczne receptora muskarynowego, kompozycja zawierająca te związki i zastosowanie tych związków
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
GB0418353D0 (en) * 2004-08-17 2004-09-22 Novartis Ag Organic compounds
WO2008130322A1 (en) 2007-04-23 2008-10-30 Astrazeneca Ab Novel 5-heterocyclyl-chromane derivatives for the treatment of pain

Also Published As

Publication number Publication date
TWI402072B (zh) 2013-07-21
EA201370052A1 (ru) 2013-11-29
US8227468B2 (en) 2012-07-24
CA2816033A1 (en) 2012-04-26
AR083364A1 (es) 2013-02-21
CA2816033C (en) 2014-04-08
CN103153989A (zh) 2013-06-12
WO2012054315A1 (en) 2012-04-26
US20120095020A1 (en) 2012-04-19
TW201231053A (en) 2012-08-01
EP2630141A1 (en) 2013-08-28
MX2013004421A (es) 2013-12-02
JP2013540154A (ja) 2013-10-31
AU2011318316A1 (en) 2013-05-02
KR20130093120A (ko) 2013-08-21

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
NZ708593A (en) Novel pyrazole derivative
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MY161001A (en) Tetrahydrocarboline Derivative
BR112012026948A2 (pt) composto, composição farmacêutica, e, métodos para melhorar o metabolismo ósseo, para previnir ou tratar uma doença associada com metabolismo ósseo e para previnir ou tratar osteoporose.
IN2014MN01183A (pt)
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
MX2011009796A (es) Inhibidores de la cinasa pi3.
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.